ClinicalTrials.gg
Not yet recruitingNCT05917600iIPAUpdated Jun 26, 2023

Impact of Advanced Practical Nursing Intervention Versus Usual Care on Hypertension Control

An interventional study of APN intervention in Hypertension, sponsored by Assistance Publique - Hôpitaux de Paris. Not yet recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-06-26.

Sponsored by Assistance Publique - Hôpitaux de Paris · Not applicable, Interventional, and Supportive care

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
330
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 18 studies in Hypertension by Assistance Publique - Hôpitaux de Paris — 6 open to participants now, 6 under way, none of them phase 3. Hypertension · Assistance Publique - Hôpitaux de Paris.

Planned enrollment
4th of 12
330 · median 210
Started
2023
the only one that year
No phase
10 of 18
3 open now
Registered
12th of 18
by date

Among the 18 studies in Hypertension by Assistance Publique - Hôpitaux de Paris, this one is the 4th largest by planned enrollment of the 12 interventional ones that give a count, is the only one that started in 2023, is one of 10 with no phase, and was the 12th registered.

Hypertension

6,128 studies on the registry are indexed under Hypertension; 907 are open to participants now.

Browse Hypertension studies →

Open to participants now

6 of the 18 studies in Hypertension by Assistance Publique - Hôpitaux de Paris are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

Where they have run

Who these studies take

Of the 552 Hypertension studies recruiting now, 260 (47%) set no upper age limit and 198 (36%) stop at 75 or younger; 40 take children under 18; 136 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies in Hypertension by Assistance Publique - Hôpitaux de Paris, or all of them as a file.
02

Study summary

Hypertension is the most frequent chronic pathology in France and in the world. It is one of the main modifiable cardiovascular risk factors. In France, 50% of treated hypertensives are uncontrolled and only 30% of treated patients are fully adherent to their antihypertensive treatment. Poor adherence to drug treatments is considered as one of the main causes of non-control of hypertension.

Since 2018, a new profession has entered the French healthcare system: Advanced Practice Nurses (APN). They have many broad skills, at the interface of nursing and medical exercises.

The purpose of this interventional study is to assess the impact of APN on blood pressure (BP) control in the context of usual care of hypertension thanks to a better adhesion of patients and a better therapeutic alliance.

The hypothesis formulated is that an individual APN intervention, included in a usual hypertension management, improves BP control.

Read the detailed description

This study will be a prospective, open-label, randomized 1-to-1 and monocentric trial, conducted at the Diagnosis and Therapeutic Center of the Hôtel-Dieu University Hospital, Assistance Publique - Hôpitaux de Paris, France.

Recruitment will be conducted during the ambulatory hospitalization. After the signature of the consent form, the randomization will be conducted during the ambulatory hospitalization. All recruited patients will be randomized.

According to the randomization, the odd-numbered participants will constitute the "usual care" group, and the even-numbered patients will constitute the "intervention" group.

The "usual care" group will keep a traditional follow-up: ambulatory hospitalization then consultation with a MD within approximately 2 to 12 months.

The "intervention" group will meet the APN between the ambulatory hospitalization and the MD consultation, within 1 to 6 months.

The participants will get their study appointment(s) (MD consultation +/- APN intervention) at the end of the ambulatory hospitalization according to their allocation.

03

Conditions studied

  • Hypertension

Keywords

  • Advanced practice nurse
  • Hypertension
  • Therapeutic adherence
  • Trial
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • At least 18 years of age,
  • Essential Hypertension
  • Hypertension management in Hôtel-Dieu Hospital
  • Ability to provide a written .

Exclusion criteria

Exclusion Criteria:

  • Have already benefited from an APN follow-up before the day of inclusion
  • Being under guardianship or curatorship
  • Pregnant patient
  • Beneficiary of the AME (state medical aid)
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
330 participants (estimated)

Study arms

  • Experimental
    Interventional group

    The interventional group meets an Advanced Practice Nurses (APN) between the ambulatory hospitalization (AH) and the MD consultation

    Other: APN intervention

  • No intervention
    Control group

    The control group of patients keeps a traditional follow-up (ambulatory hospitalization (AH) then consultation with a MD)

Interventions

  • OtherAPN intervention

    Advanced Practice Nurses (APN) intervention between the ambulatory hospitalization (AH) and the MD consultation APN intervention is divided into five main steps: * clinical and paraclinical examinations, * appraisal of patient's knowledge, * health education on hypertension and treatments, * setting a written medication plan with the patient to invest him in his management with adjusting or renewing treatments identically if necessary * decision-making balance between the benefits and risks of non-adherence to medication. A time is scheduled at the end of the intervention to let the patient ask questions or express his difficulties if he needs to.

06

What researchers measure

Primary outcomes

  1. Blood pressure control

    Blood pressure \< 140/90 mmHg

    Time frame: Medical consultation, from 2 months to 12 months after inclusion

Secondary outcomes

  1. Rate of patients who brought HBPM to consultation

    Ability to realize a home blood pressure measurement Blood pressure control in home blood pressure measurement (HBPM)

    Time frame: Medical consultation, from 2 months to 12 months after inclusion

  2. Number of measurements

    Ability of HBPM Quality of the HBPM : Number of measurements carried out over 3 days (18 measurements over 3 days according to protocol) then divided into 4 categories: performance (18 measurements), average performance (17 to 15 measurements), average performance (14 to 12 measurements or less), poor performance (11 measures or less).

    Time frame: Medical consultation, from 2 months to 12 months after inclusion

  3. Rate of Blood pressure control

    Difference between inclusion and the Medical consultation, from 2 months to 12 months after inclusion

    Time frame: Medical consultation, from 2 months to 12 months after inclusion

  4. Rate of therapeutic adjustments

    Rate of therapeutic adjustments due to side effects

    Time frame: Medical consultation, from 2 months to 12 months after inclusion

  5. Rate of therapeutic adjustments

    Rate of therapeutic adjustments due to uncontrolled hypertension

    Time frame: Medical consultation, from 2 months to 12 months after inclusion

  6. Rate of therapeutic adjustments

    Rate of therapeutic adjustments : other reason

    Time frame: Medical consultation, from 2 months to 12 months after inclusion

07

Study locations

1 site
  • Diagnosis and Therapeutic Center, Hôtel-Dieu Hospital
    Paris, IDF 75004, France
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jun 2023; primary completion for Jun 2027, 48 months later.

Of 1,407 non-industry interventional studies with no phase under Hypertension, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 41. This study's planned 48 months is above that.

Counting every sponsor, half of 1,502 studies reached it within 23 months; a quarter within 10 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 14, 2023
First posted
Jun 26, 2023
StartEst.
Jun 2023
Primary completionEst.
Jun 2027
CompletionEst.
Aug 2027
Last update
Jun 26, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 26, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05917600
Responsible party
Sponsor
First posted
Jun 26, 2023
Start date
Jun 2023 (estimated)
Primary completion
Jun 2027 (estimated)
Completion
Aug 2027 (estimated)
Last update
Jun 26, 2023

Study contacts

Juliette VAY-DEMOUY, MSc, PhD student
Contact
juliette.vaydemouy@aphp.fr
0033142348551
Marie BENHAMMANI-GODARD
Contact
marie.godard@aphp.fr
0033158411190
Jacques BLACHER, MD, PhD
principal investigator · Diagnosis and Therapeutic Center, Hôtel-Dieu Hospital, Assistance Publique-Hôpitaux de Paris
Juliette VAY-DEMOUY, MSc, PhD
study director · Diagnosis and Therapeutic Center, Hôtel-Dieu Hospital, Assistance Publique-Hôpitaux de Paris

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in May 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion